Research programme: mucopolysaccharidoses gene therapies - ESTEVE/Universitat Autonoma de Barcelona

Drug Profile

Research programme: mucopolysaccharidoses gene therapies - ESTEVE/Universitat Autonoma de Barcelona

Alternative Names: EGT 201; EGT 301; NAV rAAv9 iduronate-2-sulfatase gene therapy - Esteve/UAB; NAV rAAv9 N-acetylglucosaminidase alph gene therapy - Esteve/UAB; The Sanfilippo programme - ESTEVE

Latest Information Update: 02 Mar 2016

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Universitat Autonoma de Barcelona
  • Developer ESTEVE; Universitat Autonoma de Barcelona
  • Class Gene therapies
  • Mechanism of Action Gene transference
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Mucopolysaccharidosis III; Mucopolysaccharidosis II
  • New Molecular Entity No

Highest Development Phases

  • Preclinical Mucopolysaccharidosis II; Mucopolysaccharidosis III

Most Recent Events

  • 25 Feb 2016 Preclinical trials in Mucopolysaccharidosis II in Spain (Intracerebroventricular)
  • 25 Feb 2016 Preclinical trials of EGT 201 in Mucopolysaccharidosis III in Spain (Intracerebroventricular)
  • 25 Feb 2016 ESTEVE plans a phase I/II trial for Mucopolysaccharidosis IIIA in Spain
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top